|Table of Contents|

Clinical research progress of PARP inhibitor Olaparib in the treatment of breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3134-3138
Research Field:
Publishing date:

Info

Title:
Clinical research progress of PARP inhibitor Olaparib in the treatment of breast cancer
Author(s):
DUAN Wenwen; ZHANG Yongqiang
Department of Oncology,Beijing Hospital,National Center of Gerontology，Institute of Geriatric Medicine,Chinese Academy of Medical Sciences，Chinese Academy of Medical Sciences,Graduate School of Peking Union Medical College,Beijing 100730,China.
Keywords:
Olaparib; BRCA1/2 gene; genetic mutation; breast cancer; clinical progress
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.16.038
Abstract:
Among several inhibitors of DNA damage response pathway,PARP inhibitor is one of the more in-depth researches,which plays a key role in DNA damage repair.Olaparib,as a representative drug of PARP inhibitors,provides a new therapeutic approach for patients with early and advanced breast cancer.This paper reviews the mechanism of action,clinical efficacy and safety of PARP inhibitors in the treatment of breast cancer,so as to comprehensively understand the clinical progress of Olaparib in breast cancer and provide reference for clinical treatment and future research.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ LIU PF,ZHUO ZL,XIE F,et al.Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing［J］.Clin Chim Acta,2021,516:55-63.
［3］SUN J,MENG H,YAO L,et al.Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients［J］.Clin Cancer Res,2017,23(20):6113-6119.
［4］ DAVID BILLING,MICHIKO HORIGUCHI,FOON WU-BAER,et al.The BRCT domains of the BRCA1 and BARD1 tumor suppressors differentially regulate homology directed repair and stalled fork protection［J］.Molecular Cell,2018,72(1):127-139.
［5］ STENEHJEM DD,TELFORD C,UNNI SK,et al.BRCA testing and outcomes in women with breast cancer［J］.Breast Cancer Res Treat,2021,186(3):839-850.
［6］ LIU M,XIE F,LIU MY,et al.Association between BRCA mutational status and survival in patients with breast cancer:a systematic review and meta-analysis［J］.Breast Cancer Res Treat,2021,186(3):591-605.
［7］ CARDOSO F,PALUCH-SHIMON S,SENKUS E,et al.5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)［J］.Ann Oncol,2020,31(12):1623-1649.
［8］ LI HY,TU J,ZHAO ZQ,et al.Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas［J］.Theranostics,2020,10(21):9477-9494.
［9］ COBAIN EF,MILLIRON KJ,MERAJVER SD.Updates on breast cancer genetics:clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer［J］.Semin Oncol,2016,43(5):528-535.
［10］PILIE PG,TANG C,MILLS GB,et al.State-of-the-art strategies for targeting theDNA damage response in cancer［J］.Nat Rev Clin Oncol,2019,16(2):81-104.
［11］ ASHWORTH A,LORD CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors［J］.Nat Rev Clin Oncol,2018,15( 9):564-576．
［12］ MR MIRZA,S PIGNATA,JA LEDERMANN.Latest clinical evidence and further development of PARP inhibitors in ovarian cancer［J］.Annals of Oncology,2018,29(6):1366-1376.
［13］ KONECNY GE,KRISTELEIT RS.PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer:current practice and future directions［J］.British Journal of Cancer,2016,115(10):1157-1173.
［14］ FONG PC,BOSS DS,YAP TA,et al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers［J］.N Engl J Med,2009,361(2):123-134.
［15］MATEO J,MORENO V,GUPTA A,et al.An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib［J］.Target Oncol,2016,11(3):401-415.
［16］ MARK ROBSON,SEOCK AH IM,ELZBIETA SENKUS,et al.Olaparib for metastatic breast cancer in patients with a germline BRCA mutation［J］.The New England Journal of Medicine,2017,377(6):523-533.
［17］ SEOCK-AH IM,BINGHE XU,WEI LI,et al.Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer:OlympiAD randomized trial subgroup analysis［J］.Scientific Reports,2020,10(1):8753.
［18］ GELMON K,FASCHING P,COUCH F,et al.Real-world clinical effectiveness and safety of olaparib monotherapy in HER2 negative gBRCA-mutated metastatic breast cancer:Phase IIIb LUCY interim analysis［J］.Journal of Clinical Oncology,2020,38(15):1087.
［19］NADINE M TUNG,MARK E ROBSON,STEFFEN VENTZ,et al.TBCRC 048:Phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination-related genes［J］.Journal of Clinical Oncology,2020,38(36):4274-4282.
［20］ GAY CM,BYERS LA.PARP inhibition combined with immune checkpoint blockade in SCLC:Oasis in an immune desert or mirage［J］.J Thorac Oncol,2019,14(8):1323-1326.
［21］ SUSAN M DOMCHEK,SOPHIE POSTEL-VINAY,SEOCK-AH IM,et al.Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA):an open-label,multicentre,phase 1/2,basket study［J］.Lancet Oncology,2020,21(9):1155-1164.
［22］ CHEE KHOON LEE,CLARE SCOTT,GEOFFREY J LINDEMAN,et al.Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer,recurrent BRCA ovarian cancer,non-BRCA triple-negative breast cancer,and non-BRCA ovarian cancer［J］.British Journal of Cancer,2019,120(3):279-285.
［23］ ANBOK LEE,BYUNG-IN MOON,TAE HYUN KIM.BRCA1/BRCA2 pathogenic variant breast cancer:Treatment and prevention strategies［J］.Annals of Laboratory Medicine,2020,40(2):114-121.
［24］ ALES-MARTINEZ JE,MORALES S,FERNANDEZ ABAD M,et al.Efectiveness of olaparib plus trastuzumab in HER2［+］,BRCA-mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts).The OPHELIA study［J］.Ann Oncol,2019,30(5):139-140.
［25］ BHATTACHARYA S,SCHIEWER M,MURPHY RC,et al.A pilot trial of hyperthermia in combination with olaparib in breast cancer patients with chest wall recurrences［J］.Cancer Research,2020,80(4):OT2-03-02.
［26］ LOAP P,LOIRAT D,BERGER F,et al.Combination of Olaparib and radiation therapy for triple negative breast cancer:Preliminary results of the RADIOPARP phase 1 trial［J］.Int J Radiat Oncol Biol Phys,2021,109(2):436-440.
［27］ TUTT ANJ,GARBER JE,KAUFMAN B,et al.Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer［J］.The New England Journal of Medicine,2021,384(25):2394-2405.
［28］ EIKESDAL HP,YNDESTAD S,ELZAWAHRY A,et al.Olaparib monotherapy as primary treatment in unselected triple negative breast cancer［J］.Ann Oncol,2021,32(2):240-249.
［29］ FASCHING PA,LINK T,HAUKE J,et al.Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLAstudy)［J］.Ann Oncol,2021,32(1):49-57.
［30］ ALBA KP,MCMURTRY E,VALLIER AL,et al.Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial:addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients［J］.Cancer Research,2019,80(4):P3-10-05.
［31］ PUSZTAI L,YAU C,WOLF DM,et al.Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer:Results from the adaptively randomized I-SPY2 trial［J］.Cancer Cell,2021,39(7):989-998.
［32］DARANJIT SANDHU,ALBERT A ANTOLIN,ANTHONY R COX,et al.Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale［J］.Br J Clin Pharmacol,2022,88(2):742-752.

Memo

Memo:
-
Last Update: 1900-01-01